TheEdgeResearch
Home / Stocks / COHANCE.NS

Cohance Lifesciences Limited (COHANCE.NS)

NSE Healthcare Drug Manufacturers - Specialty & Generic
$440.65 ▼ -0.80%
Market Cap
$168.58B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.60
52-Wk Range
266.7-1038.9
CEO
Umang Vohra
Country
IN
Currency
INR

Cohance Lifesciences Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hyderabad, TS, IN. The stock last traded at $440.65, down 0.80% on the session, giving a market capitalisation of $168.58B. Its beta of 0.60 implies it has historically moved less than the broad market.

Company profile
Exchange
National Stock Exchange of India
Employees
1,193
IPO date
2020-03-09
Headquarters
Hyderabad, TS, IN
About Cohance Lifesciences Limited

Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.

Comparable companies

Cohance Lifesciences Limited is most often compared with the following Healthcare names:

ASTRAZEN.NSCOHANCE.BOERIS.NSIPCALAB.BOPEL.NSPPLPHARMA.BO
More research on COHANCE.NS
COHANCE.NS technical analysis COHANCE.NS TheEdge Score Compare against peers
Open full interactive analysis & DCF →